Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. carotid body
Show results for
Products

Companies

News
Books

Refine by
Date

  • Older

Carotid Body Articles & Analysis

11 news found

Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)

Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)

The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. It utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well tolerated in five human studies to date. ...

ByEnalare Therapeutics Inc.


Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001

Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001

"ENA-001's unique mechanism acting on the peripheral chemoreceptors in the carotid bodies enables a very rapid and effective ventilatory stimulation, irrespective of what caused the respiratory depression. ...

ByEnalare Therapeutics Inc.


Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the ...

ByEnalare Therapeutics Inc.


CVRx Launches a new Barostim Programmer

CVRx Launches a new Barostim Programmer

Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. ...

ByCVRx


Enalare Therapeutics Receives a National Institutes of Health (NIH) Grant Award

Enalare Therapeutics Receives a National Institutes of Health (NIH) Grant Award

"ENA001's differentiated approach of stimulating respiratory capacity peripherally via the chemoreceptors in the carotid body has been shown to be efficacious in both animal and human studies. ...

ByEnalare Therapeutics Inc.


Enalare Therapeutics Announces Positive Topline Results With ENA001 in a Propofol Induced Respiratory Depression Study

Enalare Therapeutics Announces Positive Topline Results With ENA001 in a Propofol Induced Respiratory Depression Study

The compound has a unique mechanism of action that affects ventilation via the peripheral chemoreceptorpathways in the carotid body. It utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well tolerated in four previous human studies. ...

ByEnalare Therapeutics Inc.


CVRx Receives MR-Conditional Labeling Approval for its Barostim Heart Failure System

CVRx Receives MR-Conditional Labeling Approval for its Barostim Heart Failure System

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. Barostim works by stimulating baroreceptors - natural sensors in the body that tell the nervous system how to regulate heart, kidney and vascular function. ...

ByCVRx


Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042

Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042

The compound has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathway in the carotid bodies. The compound utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well-tolerated in four previously completed human studies. ...

ByEnalare Therapeutics Inc.


Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity

Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity

The compound has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. The compound utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well-tolerated in four previous human studies. ...

ByEnalare Therapeutics Inc.


Enalare Therapeutics Files New Patent Application for Lead Product ENA-001 - Potentially Extending Global Exclusivity Through 2042

Enalare Therapeutics Files New Patent Application for Lead Product ENA-001 - Potentially Extending Global Exclusivity Through 2042

The product has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathway in the carotid bodies. The product utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well tolerated in four previous human studies. ...

ByEnalare Therapeutics Inc.


Enalare Therapeutics Announces First Subject Dosed With Lead Product ENA-001 in a Propofol-Induced Respiratory Depression Study

Enalare Therapeutics Announces First Subject Dosed With Lead Product ENA-001 in a Propofol-Induced Respiratory Depression Study

The product has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. The product utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well-tolerated in four previous human studies. ...

ByEnalare Therapeutics Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT